AAN 2022 | Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS

Lawrence Steinman, MD, Stanford University, Stanford, CA, shares an update on the effects of ublituximab on relapse rate. Ublituximab is a novel monoclonal antibody targeting a unique epitope on the CD20 antigen. The Phase III ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) trials evaluated the efficacy and safety of ublituximab in patients with relapsing forms of multiple sclerosis (MS). Results demonstrated that ublituximab was superior to teriflunomide in preventing relapses; relapse rate and cumulative probability of relapse were significantly reduced with ublituximab compared to teriflunomide. The anti-CD20 monoclonal antibody is currently under FDA review for the treatment of relapsing MS. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.